375 related articles for article (PubMed ID: 27081696)
1. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
2. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
3. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
4. BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma.
Wang L; Wu X; Wang R; Yang C; Li Z; Wang C; Zhang F; Yang P
Biol Res; 2017 May; 50(1):19. PubMed ID: 28545522
[TBL] [Abstract][Full Text] [Related]
5. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma.
Zhang P; Dong Z; Cai J; Zhang C; Shen Z; Ke A; Gao D; Fan J; Shi G
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):36-44. PubMed ID: 25816404
[TBL] [Abstract][Full Text] [Related]
6. The bromodomain inhibitor JQ1 up-regulates the long non-coding RNA MALAT1 in cultured human hepatic carcinoma cells.
Choi HI; An GY; Yoo E; Baek M; Binas B; Chai JC; Lee YS; Jung KH; Chai YG
Sci Rep; 2022 May; 12(1):7779. PubMed ID: 35546353
[TBL] [Abstract][Full Text] [Related]
7. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
8. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
[TBL] [Abstract][Full Text] [Related]
10. miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators.
Wang P; Chen S; Fang H; Wu X; Chen D; Peng L; Gao Z; Xie C
Oncotarget; 2016 Jan; 7(1):929-45. PubMed ID: 26498144
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
12. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Liu X; Wu H; Huang P; Zhang F
J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
14. microRNA-608 inhibits human hepatocellular carcinoma cell proliferation via targeting the BET family protein BRD4.
He L; Meng D; Zhang SH; Zhang Y; Deng Z; Kong LB
Biochem Biophys Res Commun; 2018 Jul; 501(4):1060-1067. PubMed ID: 29777702
[TBL] [Abstract][Full Text] [Related]
15. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
Wang L; Wu X; Huang P; Lv Z; Qi Y; Wei X; Yang P; Zhang F
Oncol Rep; 2016 Oct; 36(4):1989-96. PubMed ID: 27573714
[TBL] [Abstract][Full Text] [Related]
16. SOX9 is controlled by the BRD4 inhibitor JQ1 via multiple regulation mechanisms.
Hong SH; You JS
Biochem Biophys Res Commun; 2019 Apr; 511(4):746-752. PubMed ID: 30833074
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BRD4 triggers cellular senescence through suppressing aurora kinases in oesophageal cancer cells.
Xu JL; Yuan YJ; Lv J; Qi D; Wu MD; Lan J; Liu SN; Yang Y; Zhai J; Jiang HM
J Cell Mol Med; 2020 Nov; 24(22):13036-13045. PubMed ID: 32954665
[TBL] [Abstract][Full Text] [Related]
18. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
Zhou X; Fan LX; Peters DJ; Trudel M; Bradner JE; Li X
Hum Mol Genet; 2015 Jul; 24(14):3982-93. PubMed ID: 25877301
[TBL] [Abstract][Full Text] [Related]
20. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
